Literature DB >> 27900039

Networks analysis of genes and microRNAs in human Wilms' tumors.

Jimin He1, Xiaoxin Guo1, Linlin Sun2, Kuhao Wang1, Haiying Yao1.   

Abstract

Wilms' tumor (WT) is a common kidney cancer. To date, the expression of genes [transcription factors (TFs), target genes and host genes] and microRNAs (miRNAs/miRs) in WTs has captured the attention of biologists, while the regulatory association between the genes and miRNAs remains unclear. In the present study, TFs, miRNAs, target genes and host genes were considered as key factors in the construction of three levels of regulatory networks, namely, the differentially-expressed network, the related network and the global network. The four factors had three types of association, including the regulation of miRNAs by TFs, the targeting of the target genes by miRNAs and the location of miRNAs at host genes. The differentially-expressed network is the most important of the three networks, and only involves the differentially-expressed genes and miRNAs; with the exception of host genes, those elements all behave abnormally when a WT occurs, which suggests that the differentially-expressed network can accurately reveal the pathogenesis of WTs. E2F3, for example, is overexpressed in WTs, and it regulates hsa-let-7a, hsa-let-7a-1, hsa-miR-106b, among others. Meanwhile, E2F3 is targeted by hsa-miR-106b, hsa-miR-17 and hsa-miR-20a. If the regulatory network can be used to adjust those factors to a normal level, there may be a chance to cure patients with WTs. WT-associated factors were placed into the related network; this network is useful for understanding the regulatory pathways of genes and miRNA in WTs. The networks provide a novel perspective in order to study the inner interactions of genes and miRNAs. The present study provides authoritative data and regulatory pathway analysis in order to partially elucidate the pathogenesis of WT, and thus supplies biologists with a basis for future research.

Entities:  

Keywords:  Wilms' tumor; host gene; miRNA; network; target gene; transcriptional factor

Year:  2016        PMID: 27900039      PMCID: PMC5104055          DOI: 10.3892/ol.2016.5102

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  19 in total

1.  Gene regulation by transcription factors and microRNAs.

Authors:  Oliver Hobert
Journal:  Science       Date:  2008-03-28       Impact factor: 47.728

2.  Regulatory network analysis of microRNAs and genes in neuroblastoma.

Authors:  Li Wang; Xiang-Jiu Che; Ning Wang; Jie Li; Ming-Hui Zhu
Journal:  Asian Pac J Cancer Prev       Date:  2014

Review 3.  Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor.

Authors:  J B Beckwith; N B Kiviat; J F Bonadio
Journal:  Pediatr Pathol       Date:  1990

4.  Association of E2F3 expression with clinicopathological features of Wilms' tumors.

Authors:  Qun An; Yan Wang; Ruihua An; Yan Li; Ting Yao; Bo Zhai; Xueying Sun
Journal:  J Pediatr Surg       Date:  2013-11       Impact factor: 2.545

5.  Local gene regulation details a recognition code within the LacI transcriptional factor family.

Authors:  Francisco M Camas; Eric J Alm; Juan F Poyatos
Journal:  PLoS Comput Biol       Date:  2010-11-11       Impact factor: 4.475

6.  Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene.

Authors:  A Koch; D Denkhaus; S Albrecht; I Leuschner; D von Schweinitz; T Pietsch
Journal:  Cancer Res       Date:  1999-01-15       Impact factor: 12.701

7.  Identification of mammalian microRNA host genes and transcription units.

Authors:  Antony Rodriguez; Sam Griffiths-Jones; Jennifer L Ashurst; Allan Bradley
Journal:  Genome Res       Date:  2004-09-13       Impact factor: 9.043

8.  Networks of MicroRNAs and genes in retinoblastomas.

Authors:  Jie Li; Zhi-Wen Xu; Kun-Hao Wang; Ning Wang; De-Qiang Li; Shang Wang
Journal:  Asian Pac J Cancer Prev       Date:  2014-01

9.  The UCSC Genome Browser database: update 2011.

Authors:  Pauline A Fujita; Brooke Rhead; Ann S Zweig; Angie S Hinrichs; Donna Karolchik; Melissa S Cline; Mary Goldman; Galt P Barber; Hiram Clawson; Antonio Coelho; Mark Diekhans; Timothy R Dreszer; Belinda M Giardine; Rachel A Harte; Jennifer Hillman-Jackson; Fan Hsu; Vanessa Kirkup; Robert M Kuhn; Katrina Learned; Chin H Li; Laurence R Meyer; Andy Pohl; Brian J Raney; Kate R Rosenbloom; Kayla E Smith; David Haussler; W James Kent
Journal:  Nucleic Acids Res       Date:  2010-10-18       Impact factor: 16.971

10.  miRNA profiles as a predictor of chemoresponsiveness in Wilms' tumor blastema.

Authors:  Jenny A Watson; Kenneth Bryan; Richard Williams; Sergey Popov; Gordan Vujanic; Aurore Coulomb; Liliane Boccon-Gibod; Norbert Graf; Kathy Pritchard-Jones; Maureen O'Sullivan
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

View more
  4 in total

1.  MicroRNA-27a-5p Inhibits Proliferation, Migration, and Invasion and Promotes Apoptosis of Wilms' Tumor Cell by Targeting PBOV1.

Authors:  Zheng-Tuan Guo; Qiang Yu; Chunlin Miao; Wenan Ge; Peng Li
Journal:  Mol Cell Biol       Date:  2022-07-11       Impact factor: 5.069

2.  MiR-1180-5p regulates apoptosis of Wilms' tumor by targeting p73.

Authors:  Xiuyun Jiang; Huaicheng Li
Journal:  Onco Targets Ther       Date:  2018-02-16       Impact factor: 4.147

3.  Comprehensive Analysis of a Long Noncoding RNA-Associated Competing Endogenous RNA Network in Wilms Tumor.

Authors:  Feng Zhang; Liping Zeng; Qinming Cai; Zihao Xu; Ruida Liu; Haicheng Zhong; Robert Mukiibi; Libin Deng; Xiaoli Tang; Hongbo Xin
Journal:  Cancer Control       Date:  2020 Apr-Jun       Impact factor: 3.302

4.  miRNA Profiling of Hungarian Regressive Wilms' Tumor Formalin-Fixed Paraffin-Embedded (FFPE) Samples by Quantitative Real-Time Polymerase Chain Reaction (RT-PCR).

Authors:  Gergely Buglyó; Zsófia Magyar; Éva Romicsné Görbe; Rita Bánusz; Monika Csóka; Tamás Micsik; Márta Mezei; Jaxi Ayman Shawky Yani; Péter Varga; Zoltán Sápi; Bálint Nagy
Journal:  Med Sci Monit       Date:  2021-10-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.